Observational Advanced Age Study for RMS Patients Treated with Cladribine Tablets

A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (≥ 50 years) Treated with Cladribine Tablets

  • Clinical Trial Information

    Trial Contact: Carlo, Charlene S; Monserrate, Francheska; Mondragon, Diana; Melendez, Thomas L; Flores-Vega, Mariangelis

  • IRB No: 22.131.06

    Protocol Abbrev: Aging Study

    Principal Investigator: Amy (Amparo) Gutierrez, MD, FAAN

    Age Group: Adult

    Secondary Protocol No: MS700568_0185

    Treatment: N/A- Observational study

    Therapies Involved: Medication

  • Objective

    To estimate the annualized relapse rate (ARR) over 24 months after cladribine tablet initiation in a
    real world, US cohort of patients with RMS who are aged 50 years or older at the time of cladribine
    tablet initiation

  • Key Eligibility

    Adults aged 50 or older at the start of cladribine tablets, on or before January 2022, with definite RMS or active SPMS